Member Info for Dinoken

sp has smashed clean thru resistance 1 & 2. There is no upper limit in sight except for that broker forecast of 22 !!!!!!!!!

Reuters : A new AstraZeneca inhaler for chronic lung disease has proved worse than a rival GlaxoSmithKline product in a clinical trial, a result AstraZeneca said was inconsistent with earlier findings.

Bevespi Aerosphere - a combination of two kinds of drugs known as LAMA and LABA - was as good as GSK's Anoro in improving peak breathing levels when patients exhaled but it failed to match Anoro on trough measures, AstraZeneca said on Thursday.

Quite agree that flights will be cancelled all of the time for any number of reasons, causing all manner of personal problems to passengers. Just find it hard to believe that Flybe has not established sufficient rapport with local rags to prevent stories like this being published in first place. A few complimentary tickets (to demonstrate the fantastic Flybe service) should do the trick.

No news or broker notes that I can find. Anyone got an explanation for this sudden rise ?

About time Flybe got a handle on what to do to prevent publicity like this.
Camborne mum slams Flybe for nightmare journey consisting of cancelled flight and 'atrocious' customer service etc..
https://www.cornwalllive.com/news/cornwall-news/camborne-mum-slams-flybe-nightmare-1919516

Had not appreciated extent of FAS involvement with RAF before. Suddenly the reason for Timo's appointment becomes clear. Got any figures for the monetization ?

Probably signals end of rally which I thought was en route to £17 ...
Interesting that EPS growth could be up by 17%
For those who cannot be bothered to link to fool, read on :
Defensive income
GlaxoSmithKline (LSE: GSK) is another name on my list of top FTSE 100 income stocks.
Last year, shares in Glaxo plunged when speculation began to emerge that the company was planning a cut to its dividend payout of 80p per share. Even though management has since stated that it is committed to the distribution, investors have been slow to return.
Over the past few months, sentiment has begun to recover. The stock is up around 28% since the beginning of February. New product launches and better than expected sales growth have helped the company regain investor trust. City analysts now believe the group can achieve EPS growth of 17% for the full year. Based on these figures, the shares are trading at a forward P/E of 14.3, an undemanding multiple in my opinion considering Glaxo’s growth potential and defensive nature.
Shares in the company also support a dividend yield of 5.1%.

Positive thinking from HSBC : Analysts at HSBC sounded a more positive note on RBS and Barclays on Friday, but not Lloyds, following the 15-20% decline in their share prices over the past three months, on the back of concerns around geopolitics (and Brexit).

Nevertheless, while valuations for the three lenders had improved, with all of them now looking simply 'oversold', their 'operating story' had not, they said.

They were particularly more upbeat on RBS, raising their target price on its stock from 280p to 290p, while upgrading their recommendation from 'hold' to 'buy'.

Barring a 'hard Brexit', or other significant 'macro issues', RBS should see "modest" revenue growth, HSBC said.

More importantly however, the shares had underperformed those of its peers as hedge funds looked to turn a quick profit from the government's sale on 5 June of a 7.7% stake in the lender.

With scant liquidity in the market, their price took a hit as the hedge funds sold, with institutional investors having remained on the sidelines during the placing for a "variety of reasons".

But another placing by the government was deemed unlikely in the near-term and RBS should be able to begin buying stock in early 2019, thus reducing the overhang in its shares, HSBC said.

What an advert for the bank. According to Times, RBS had to put up posters in all its branches letting everyone know it had managed to achieve bottom of the league table for customer service. On reflection, if my experience with three other banks is anything to go by, coming last took some doing ...

Beyond belief ...
http://www.dailymail.co.uk/news/article-6065021/RBS-Royal-Bank-Scotland-threatens-Europe-hard-Brexit.html

Jambon - fred certainly walked away ok, very sorry to hear about the staff suicides. Bemused to hear that his office has been left exactly as it was when he left (no kidding), I presume as a shrine to his extraordinary achievement in nearly bringing down capitalism more effectively than any number of socialist/communist figures have ever managed in the past.

IMO - todays announcement about the HIV treatment is a very significant breakthrough. Not surprised sp has responded well in declining market. In fact, surprised it did not do even better. Think there is more to come ...
"Promising results from a study lifted shares in Britain's biggest drugmaker GlaxoSmithKline 1.9 percent. A long-acting injection developed by GSK has proved as effective as standard daily pills for controlling the AIDS virus.
This has lifted prospects for Glaxo's key HIV business.
"GSK has now delivered positive data from all three of the key elements making up its strategy of offering patients a move to less toxic dual therapy with the option of a monthly injectable," analysts at Liberum said in a note, adding that the prospects for dual-drug therapy were much improved compared with a year ago".

Britain's first mandatory sector-wide customer survey to help people choose the best bank has seen RBS putting in a sterling performance and making it to joint last (15th) ! Surprised RBS were not completely at bottom of pile. On a brighter note, Natwest were joint 9th.

Just enjoying a pint of Brakspears double-drop bitter and by accident found MARS tipped by of all people Motley Fool. This usually results in complete disaster for the sp of the company concerned. The article describes Marston's as a pub operator - completely overlooking the fact that it brews some great beer. However, some of the figures are worth serious consideration (PE 6.5) and MARS does look ridiculously dirt cheap.
For those who cannot be bothered to access Fool, main points below.
"It goes without saying that the tough economic environment has clouded the outlook for many of Britain’s listed publicans. That said, this smallcap stock has shown marvellous resilience while many of its rivals have struggled.
Indeed, sales performance has picked up in the second half of the fiscal year. In the 42 weeks to July 21, like-for-like sales were up 0.3%, with comparable revenues rising 0.9% in the most recent 16 weeks, thanks in part to the good weather and the FIFA World Cup. And in the 12 weeks since April, a month which was beset with bad weather, like-for-like sales rose 2%.
Marston’s is expected to endure a 2% earnings reversal in the year to September 2018, but helped by ongoing expansion it is expected to fire back with a 5% rise next year. This means that the firm carries a forward P/E ratio of just 6.8 times, and also that dividends should continue rising as well.
Last year’s 7.5p per share reward is anticipated to rise to 7.6p this year and to 7.8p in fiscal 2019, projections that create mountainous yields of 8.1% and 8.3% respectively. The pub operator is worth a serious look at current prices, in my opinion".

Interesting note from UBS on Friday which mentions Buybacks and risks of Brexit.
Brexit bit is scaremongering IMO :
"RBS shares rise as it looks to pay first dividend since financial crisis, posts first half profit
A US$4.9bn settlement with the US Department of Justice (DoJ) over the sale of mortgage-backed securities in the run-up to the financial crisis, marked the last of the bank’s major legacy issues and paved the way for the resumption of dividends.
RBS recommended an interim dividend of 2p as it reported an attributable profit of £888mln for the six months ended June 30, down from £939mln last year, with the decline reflecting its settlement with the DoJ.
“The first dividend in a decade didn't dent the balance sheet either: significant special dividends or buybacks – perhaps direct from government – are needed to stop this undervalued surplus capital from growing further,” UBS said.
“We think earnings and excess capital are undervalued at a buyback-adjusted medium term price-earnings of 6-7x; upgrade to Buy.”
UBS expects higher dividend yield, share buybacks
RBS is targeting earnings per share (EPS) of 34p in 2020 and while UBS is “more cautious” with its estimate of 28p, it expects £5bn in share buybacks to the end of 2021 to take the stock to 6.5 times earnings.
UBS estimates a dividend yield of 3.4% in 2018, rising to 5.0% in 2020, along with buybacks and special dividends to reduce overcapitalisation.
In 2019, UBS expects RBS to ask shareholders for approval to repurchase stock direct from the UK government, reducing the overhang, increasing index weights and delivering EPS accretion.
The government sold 925mln of its shares in RBS in June, reducing its stake to 62.4% from 70.1%.
Risk of no-deal Brexit
With any company, there are of course risks, and a no-deal Brexit scenario is a major one facing RBS.
“If negotiations fail we would expect pressure from margins (Bank of England to cut rates and restart quantitative easing), loan losses (lower house prices, weaker macro-economic assumptions under IFRS 9) and higher risk-weighted assets density,” UBS said.
“We don't kid ourselves that discounted valuations would provide protection. But a no-deal Brexit is also not our base case given significant apparent risks to financial stability for both sides of the negotiating table: we see room for UK domestic bank exposure in any portfolio.”

IMO - Ergen is just trying to save face after his ridiculous offer was rejected and made public. The USA laws about talks are virtually the same as the UK ones so I do not put any faith in his statement whining about UK disclosure :

British takeover laws forced the divulgence of EchoStar’s talks with Inmarsat, a regulatory snag that might have soured negotiations with Inmarsat prematurely, Ergen said.
“Normally we have those kinds of conversations in private,” he said. “If companies can find a way to put some assets together and work together, we typically like to do that in private. Many times companies have honest disagreements as to valuations, and so things don’t happen, but at least it’s not in the public eye. I think that was probably detrimental.”

'bought low' ? Good luck with that. If next gov sale is at 4% discount to mkt price and then followed by a further 8% decline thereafter - this would imply you have not 'bought low' at all. Last gov sale was for 7% meaning there are about 7 more gov sales to go … Extrapolating the falls encountered by the last sale - that implies sp of about less than 200 before gov sales complete.

londoner7 - how can you call yourself 'Londoner' if you live in Scotland ? Now that Fish Face (cannot remember her name - Salmond/Trout/Sturgeon ?) has introduced her booze tax, will you be coming home ? Is the price of a real ale north of the border now higher than the south ?

From today's Telegraph - not good for RBS sentiment. Interesting insight on government sell off. Not sure how they will get the next sale right ...
"RBS sell-off may be slowed if share sale flops again, warn analysts
Investors who took part in the first Government sale of RBS stock in three years earlier this summer would lose around £125m on their £2.5bn outlay if they were to sell today. The City is nervously awaiting a further sale of the taxpayers’ remaining 62.4pc stake in the bank, after a poor outing last time round in June. RBS cheered fund managers on Friday when it announced its first dividend in a decade since its £45bn bailout at the height of the financial crisis. It unveiled a 2p interim dividend after a quarter of solid profits.
However, industry sources warned that a second underwhelming sale of government stock could slow the privatisation of RBS. “If they want to privatise it quickly they need to get the next one right,” one senior investor said.
The last sale saw the Treasury ­offload a 7.7pc chunk of the state-controlled lender, at a price of 271p a share, for £2.5bn. This was 10p lower than the previous day’s closing price of 281p, and the stock fell a further 15p on the day to 266p. RBS shares have fallen further since the sale, despite a 3pc rally on Friday following the dividend news.
The stock finished last week at 258p, which is 5pc down on the 271p level new investors bought in at in June. That would translate to a £125m loss on the £2.5bn of shares bought. Commenting on June’s share sale after the bank’s half-year results on Friday, RBS chief executive Ross McEwan blamed market volatility for the fall. He said: “They sold £2.5bn worth of stock which is a huge undertaking. I think what then happened afterwards – you saw some quite dramatic changes in the marketplace which brought the stock down. “But £2.5bn is no small amount to get out into the marketplace, it took a while to absorb it. “Let’s see what the Government do next, they’ve now got a business that has the intention to pay a dividend which should be helpful and it’s in their hands as to when they sell the next tranche.” Mr McEwan said the bank hoped to quickly build the dividend over time to around 40pc of earnings, but warned that a chaotic Brexit could slow the process down. “We need to take a look at that ­before making major capital distributions,” he said. UK Government Investments – which manages the Treasury’s RBS stake – was unavailable for comment.

Article in Daily Mail today about cost of beer in pubs and fact that more pubs will inevitably close - heard most of this before. Suspect this is already built into MARS sp,but still dents sector sentiment..
However, what I have never understood is the huge difference in cost of pint in different parts of country. The article states that average cost of pint of bitter is £3.05 !! This would be good news to me - local pubs hereabouts charge £3.95 to £4.20 !! Conversily, 500 bottle of Pedigree from LIDL is £1.25. Not surprising pubs cannot compete ...

http://www.dailymail.co.uk/news/article-6029483/Now-think-pints-unaffordable-cost-lager-rose-3-58-year.html
For those who cannot be bothered to follow the link, excerpt below :
Death of the local
Gone are the days when you would hardly have to factor a round or two into your weekly budget.
The majority of Britons now think the cost of pint is unaffordable, according to a study by the Campaign for Real Ale (Camra). Just one in four believe prices are ‘about right’, the survey of more than 2,000 adults found.
Last year the average price of a pint of bitter rose 6p to £3.05, with that of a pint of lager up 10p to £3.58, according to the British Beer and Pub Association.
Camra said a third of the price of a pint is made up of taxes including beer duty, business rates and VAT – and voiced concern that rising prices will lead to more pub closures. Jackie Parker, Camra’s chairman, said: ‘Beer drinkers will naturally look to more cost-effective ways to enjoy a drink, such as buying from off-licences.
‘The result is incredibly detrimental to our local communities and to our own personal connectivity. Having a good local makes people happier, better-connected and more trusting.’